Scientists Race to Test Ebola Treatments as Congo Outbreak Spreads Into Displacement Camps

Global health agencies and researchers are accelerating efforts to test experimental Ebola vaccines and treatments as a rapidly growing outbreak in the Democratic Republic of Congo spreads into overcrowded displacement camps already struggling with conflict, poor sanitation and collapsing medical infrastructure.

The urgency surrounding the outbreak intensified after aid agencies confirmed Ebola-related deaths inside the Kpangba displacement camp, where tens of thousands of internally displaced people are living in densely packed conditions. Reuters reported that two infected people died after the virus reached the camp, raising fears of accelerated community transmission.

Health officials now say the outbreak has become one of the largest Ebola emergencies in recent years — and unlike previous Ebola waves, this one involves the Bundibugyo strain, which currently has no approved vaccine or treatment.

Congo’s Ebola Outbreak Is Expanding Faster Than Response Systems

The exact catalyst driving the latest global attention is the combination of three escalating developments:

• the outbreak’s spread into displacement camps,
• the rising confirmed death toll,
• and the absence of approved Bundibugyo-specific medical countermeasures.

According to Reuters, Congo reported nearly 600 confirmed Ebola cases earlier this week. Updated figures published Thursday showed confirmed infections rising to 676 cases with 136 deaths, while neighboring Uganda has also reported confirmed cases.

The World Health Organization previously declared the outbreak a Public Health Emergency of International Concern after cross-border transmission risks increased between Congo and Uganda. WHO warned that the outbreak may be significantly larger than early surveillance initially detected.

Researchers and humanitarian groups say conflict conditions in eastern Congo have made contact tracing and isolation efforts substantially harder than in previous Ebola responses.

📰 Related: Ebola Confirmed in Congo Camp of 30,000 — 676 Cases, 136 Deaths

Scientists Are Testing Experimental Vaccines and Antivirals

The procedural trigger behind the current medical race is simple:

there are no licensed treatments specifically approved for the Bundibugyo strain of Ebola.

That has pushed international agencies, pharmaceutical companies and research organizations into accelerated emergency development programs.

According to Reuters, several experimental vaccine platforms are now being prioritized, including:

• Oxford University’s ChAdOx1 Bundibugyo vaccine,
• Moderna’s mRNA Ebola candidate,
• and multiple rVSV-based vaccine projects supported by CEPI.

Researchers are also evaluating antiviral drugs and monoclonal antibody therapies including:

• remdesivir,
• obeldesivir,
• MBP134,
• and Regeneron-linked antibody treatments originally designed for other Ebola strains.

The challenge is that many of these therapies remain in preclinical or limited-trial stages, meaning scientists are attempting to compress years of testing and deployment work into a rapidly evolving outbreak environment.

📰 Related: World Cup 2026 and Infectious Disease — What Health Experts Are Actually Watching

Testing Shortages and Conflict Zones Are Slowing the Response

Even basic diagnostic systems are under pressure.

Reuters reported that Ebola testing stalled in several Congolese laboratories because of shortages involving key testing materials and reagents.

The outbreak is unfolding across provinces already affected by armed conflict, militia violence and large-scale displacement.

Aid workers say mistrust toward outside medical teams is also complicating containment efforts. In some communities, infected people reportedly avoided quarantine centers or were buried without formal health supervision, increasing transmission risks.

Medical supply chains have also been strained. Reuters reported that frontline responders in some areas are running short of protective equipment including boots, face shields and chlorine supplies.

📰 Related: WHO Warns 40 Million Children Are Already Addicted — and 160 Countries Have No Nicotine Pouch Rules

Why the Bundibugyo Strain Is Alarming Health Officials

Most modern Ebola countermeasures were developed around the Zaire strain, which caused several earlier major outbreaks in Africa.

The Bundibugyo strain is rarer and far less studied.

That distinction is now becoming one of the central global health concerns surrounding the outbreak because doctors cannot rely on the same treatment infrastructure used during prior Ebola emergencies.

The WHO said the outbreak is particularly dangerous because existing vaccine stockpiles may not provide reliable protection against Bundibugyo infections.

Researchers are now trying to determine:

• whether existing Ebola antivirals can reduce mortality,
• how quickly emergency vaccine trials can begin,
• and whether transmission can be slowed before the virus spreads further into urban centers or across additional borders.

What Happens Next in the Ebola Response

The next phase of the response will likely focus on three priorities:

• expanding testing capacity,
• accelerating emergency treatment trials,
• and preventing further spread inside displacement camps.

The United States this week announced an additional $50 million contribution to CEPI to support Ebola countermeasure development and manufacturing efforts, according to Reuters.

Scientists warn, however, that medical breakthroughs alone may not be enough.

Containment efforts still depend heavily on:

• local trust,
• rapid isolation,
• protective equipment access,
• and the ability to safely operate inside conflict-affected regions.

Key Takeaways

• Congo’s Ebola outbreak has expanded into overcrowded displacement camps.
• The outbreak involves the Bundibugyo Ebola strain, which has no approved vaccine or treatment.
• Scientists are accelerating trials involving experimental vaccines, antivirals and antibody therapies.
• Testing shortages and conflict conditions are slowing containment efforts.
• Global health officials warn the outbreak could continue spreading without faster intervention.

Sources

• Reuters — Ebola outbreak spreads to crowded displacement camp in Congo
• Reuters — What Bundibugyo Ebola vaccines and treatments are under development
• Reuters — Ebola testing stalled in three Congo labs due to shortages
• WHO — Ebola outbreak declared public health emergency
• Reuters — US to provide $50 million more to counter Ebola outbreak

Also Read

• Postpartum Hemorrhage Kills 43,000 Women a Year — and 95% of Deaths Are Preventable
• Remote Work Is Making You Depressed — Major Study Confirms It
• GLP-1 Drugs: The Promises and the Troubling Side Effects Nobody Told You About